A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection
This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
In this study patients will be treated with a combination therapy to determine if this combination can effectively treat COVID-19. Treatment will last ten days. The study will last 24 weeks.
Exclusion Criteria
Refusal to provide informed consent
Diarrhea prior to infection
Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject
Any contraindications for treatment with hydroxychloroquine
Anemia from pyruvate kinase and G6PD deficiencies
Abnormal EKG with QT prolongation acquired or from birth
Allergies to 4-Aminoquinolines
History of jaundice or high fevers prior to developing COVID-19
Treatment with any of the medications listed in Appendix II
Treatment with any other drug not listed that affects the QT interval
Treatment with any anti-epileptic drug, whether prescribed for seizures or otherwise.
Pregnant or breastfeeding women